{"id":"motixafortide-g-csf","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Splenomegaly"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Motixafortide blocks the CXCR4 chemokine receptor on hematopoietic stem cells, disrupting their retention in the bone marrow microenvironment. When combined with G-CSF, which stimulates stem cell proliferation and mobilization, this dual mechanism significantly increases the number of CD34+ cells available for collection in autologous stem cell transplantation procedures. This combination improves mobilization efficiency, particularly in patients who are poor mobilizers.","oneSentence":"Motixafortide is a CXCR4 antagonist that mobilizes hematopoietic stem cells from bone marrow into peripheral blood, used in combination with G-CSF (granulocyte-colony stimulating factor) to enhance stem cell mobilization for transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:13.696Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematopoietic stem cell mobilization in patients with multiple myeloma or lymphoma undergoing autologous stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT06514508","phase":"PHASE3","title":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2025-12-01","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT06547112","phase":"PHASE1","title":"A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2024-10-31","conditions":"Multiple Myeloma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BL-8040+G-CSF"],"phase":"phase_3","status":"active","brandName":"Motixafortide+G-CSF","genericName":"Motixafortide+G-CSF","companyName":"Guangzhou Gloria Biosciences Co., Ltd.","companyId":"guangzhou-gloria-biosciences-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Motixafortide is a CXCR4 antagonist that mobilizes hematopoietic stem cells from bone marrow into peripheral blood, used in combination with G-CSF (granulocyte-colony stimulating factor) to enhance stem cell mobilization for transplantation. Used for Hematopoietic stem cell mobilization in patients with multiple myeloma or lymphoma undergoing autologous stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}